dexamethasone / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

194 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dexamethasone / Generic mfg.
FUMANBA-03, NCT06464991: A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM

Recruiting
3
240
RoW
Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone
Nanjing IASO Biotechnology Co., Ltd.
Multiple Myeloma
08/27
12/30
COSMIC, NCT04828525: Corticosteroids as an Additional Treatment for Mastoiditis In Children

Not yet recruiting
3
50
NA
Dexamethasone, normal saline
ori snapiri
Mastoiditis; Acute
03/24
07/24
IFM2020-05, NCT04751877: Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

Active, not recruiting
3
270
Europe
Isatuximab, Lenalidomide, Bortezomib, Dexamethasone
Poitiers University Hospital, Intergroupe Francophone du Myelome, Sanofi
Multiple Myeloma, Myeloma
04/24
08/27
NCT06216158: Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

Recruiting
3
411
Europe
Iberdomide, Isatuximab, Sarclisa, Dexamethasone
University of Heidelberg Medical Center, KKS Netzwerk, Wuerzburg University Hospital, Sanofi, Bristol-Myers Squibb
Multiple Myeloma
12/28
06/29
NCT06182774: Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

Recruiting
3
559
Canada
Daratumumab, Lenalidomide, Dexamethasone
Canadian Cancer Trials Group, Canadian Institutes of Health Research (CIHR), Myeloma Canada
Multiple Myeloma
01/32
07/32
TREAT-SC, NCT06259006: Early, Short Course Oral Dexamethasone for the Treatment of Sydenham Chorea in Children

Not yet recruiting
3
80
RoW
Dexamethasone Oral, Placebo
Starship Child Health, Te Toka Tumai Auckland, Health Research Council, New Zealand, Menzies School of Health Research
Rheumatic Fever, Sydenham Chorea
05/27
05/28
NCT06331520: NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens

Not yet recruiting
3
627
NA
Netupitant / Palonosetron Oral Capsule [Akynzeo], Olanzapine, Dexamethasone Oral
Fudan University
Chemotherapy-induced Nausea and Vomiting, Highly Emetogenic Chemotherapy
05/25
05/26
ALUMMINATE, NCT06232707: A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Withdrawn
3
466
Europe, Canada, Japan, US, RoW
Alnuctamab, BMS-986349, CC-93269, Pomalidomide, POMALYST®, IMNOVID®, CC-4047, BMS-986379, Daratumumab, DARZALEX®, DARZALEX, FASPRO®, Elotuzumab, Empliciti®, BMS-901608, Carfilzomib, KYPROLIS®, Dexamethasone
Celgene
Multiple Myeloma
11/25
09/30
NCT06158841: Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
3
380
Europe, RoW
ABBV-383, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone
AbbVie
Multiple Myeloma
12/27
01/28
NCT05405166 / 2021-002485-41: SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

Active, not recruiting
3
534
Europe, Canada, Japan, US, RoW
Isatuximab IV, SAR650984, SARCLISA®, Isatuximab SC, Dexamethasone, Pomalidomide, Pomalyst or equivalent, Montelukast, Paracetamol / Acetaminophen, Diphenhydramine, Methylprednisolone
Sanofi, Sanofi-aventis recherche & developpement
Plasma Cell Myeloma Recurrent
11/24
03/27
NCT03952091: TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Checkmark Initiation of pivotal trial in multiple myeloma
May 2019 - May 2019: Initiation of pivotal trial in multiple myeloma
Completed
3
289
RoW
TJ202, Lenalidomide and Dexamethasone, Lenalidomide and Dexamethasone
TJ Biopharma Co., Ltd.
Multiple Myeloma in Relapse, Refractory Multiple Myeloma
06/24
06/24
ADELA, NCT06382948: Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

Not yet recruiting
3
240
NA
Everolimus, Zortress, Votubia, RAD001, Certican, Afinitor, Elacestrant, ER-306323, RAD1901, Selective estrogen receptor degrader/selective estrogen receptor modulator (SERD/SERM) RAD1901, Placebo, Auxiliary Medicinal Product - Dexamethasone, Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues
MedSIR, Stemline Therapeutics, Inc.
Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation
09/27
04/28
MK-2870-009, NCT06305754: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

Recruiting
3
520
US, RoW
Sacituzumab tirumotecan, SKB264, MK-2870, Pemetrexed, Carboplatin, Antihistamine, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent)
Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC)
09/28
06/30
KRdvsRd, NCT04096066: A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant

Active, not recruiting
3
84
Europe
Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone
Fondazione EMN Italy Onlus
Multiple Myeloma, New Diagnosis Tumor
07/24
07/24
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Active, not recruiting
3
150
RoW
SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone)
Antengene Corporation
Relapsed or Refractory Multiple Myeloma
07/24
10/24
NCT05564286: Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer

Completed
3
116
RoW
Fosaprepitant, shanqi, tropisetron, luoting, Dexamethasone, xiluoan
Shantou University Medical College
Cervical Cancer, Nasopharyngeal Cancer, Chemotherapy-induced Nausea and Vomiting, Radiation-Induced Nausea and Vomiting, Antiemetic
07/23
08/23
NCT02102789: A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis

Recruiting
3
142
RoW
mFOLFOX6, Oxaliplatin, Leucovorin, 5-fluorouracil, HAI, floxuridine (FUDR), dexamethasone
Yuhong Li
Metastatic Colorectal Cancer
08/24
12/24
TT4B, NCT00734877: UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma

Active, not recruiting
3
382
US
M-VTD-PACE, Melphalan, Velcade, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide, TT3-LITE Regimen (L-TT3), Velcade (bortezomib)
University of Arkansas, Millennium Pharmaceuticals, Inc.
Multiple Myeloma
09/25
09/26
NCT02516423: Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone

Active, not recruiting
3
11
US
ixazomib, lenalidomide, dexamethasone, zoledronic acid
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Millennium Pharmaceuticals, Inc., Biologics, Inc.
Solitary Osseous Plasmacytoma
09/24
 
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Calendar Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
Calendar Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jul 2023 - Dec 2023: Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial)
Jul 2023 - Dec 2023: Acceptance of regulatory submission in US for 2L+ multiple myeloma (based on DREAMM-8 trial)
Jul 2023 - Dec 2023: Acceptance of regulatory submissions in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
More
Recruiting
3
357
Europe, Japan, US, RoW
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
GlaxoSmithKline
Multiple Myeloma
01/24
05/29
GEM-CLARIDEX, NCT02575144 / 2015-001183-19: Ld vs BiRd

Active, not recruiting
3
286
Europe
Clarithromycin, Lenalidomide, Dexamethasone
PETHEMA Foundation, Cabyc, S.L.
Multiple Myeloma
10/24
10/24
iMMagine-3, NCT06413498: A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Not yet recruiting
3
450
NA
Anitocabtagene Autoleucel, CART-ddBCMA, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib
Kite, A Gilead Company, Arcellx, Inc.
Multiple Myeloma
07/28
07/31
ML43171, NCT05306340 / 2022-000199-20: A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Recruiting
3
320
Europe, Japan, US, RoW
Giredestrant, GDC-9545, RO7197597, RG6171, Exemestane, Fulvestrant, Tamoxifen, Everolimus, LHRH Agonist, Dexamethasone Mouth Rinse
Genentech, Inc.
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
10/24
03/26
ATLAS, NCT02659293: Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

Active, not recruiting
3
180
Europe, US
Lenalidomide, Revlimid, Carfilzomib, Kyprolis, Dexamethasone, Lenalidomide (Control)
University of Chicago
Multiple Myeloma
11/24
11/26
FiTNEss, NCT03720041 / 2018-003590-10: Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

Recruiting
3
740
Europe
R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, Ninlaro, Revlimid, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide plus placebo maintenance, R2: Lenalidomide + ixazomib maintenance
University of Leeds, Cancer Research UK, Takeda, Celgene
Multiple Myeloma
12/24
12/24
FINISHER, NCT05132920: Fight INflammation to Improve Outcome After Aneurysmal Subarachnoid HEmorRhage

Recruiting
3
334
Europe
Dexamethasone, Placebo
University Hospital, Bonn, German Federal Ministry of Education and Research, Pharmacy of the University Hospital Leipzig- AöR, nextevidence GmbH
Aneurysmal Subarachnoid Hemorrhage
12/24
12/25
NCT04504825 / 2019-004254-28: A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis

Active, not recruiting
3
124
Europe, Canada, Japan, US, RoW
CAEL-101, Placebo, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
Alexion Pharmaceuticals, Inc.
AL Amyloidosis
12/24
12/26
Dex-Fib, NCT04655144: Dexamethasone for Post Uterine Artery Embolization Pain

Active, not recruiting
3
82
US
Dexamethasone, Saline
University of Miami
Leiomyoma
12/24
12/24
(COBRA), NCT03729804: Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma

Recruiting
3
250
US
Carfilzomib, Kyprolis, Lenalidomide, CC-5013, Revlimid, Dexamethasone, Bortezomib, Velcade, PS-341
University of Chicago
Multiple Myeloma
12/24
12/24
MAGNETISMM-5, NCT05020236 / 2021-000044-22: MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Recruiting
3
761
Europe, Canada, Japan, US, RoW
Elranatamab, PF-06863135, Daratumumab, Darzalex Faspro; Darzalex solution for injection, Pomalidomide, Pomalyst, Imnovid, Dexamethasone
Pfizer
Multiple Myeloma
08/25
05/27
NCT03567473: Bronchiolitis in Infants Placebo Versus Epinephrine and Dexamethasone Study

Recruiting
3
864
Canada, RoW
Oral dexamethasone, Dexamethasone, Nebulized Epinephrine, Nebulized Adrenaline, Oral placebo, Placebo, Nebulized normal saline, Saline, MDI Epinephrine, MDI Adrenaline, MDI placebo
Children's Hospital of Eastern Ontario, Canadian Institutes of Health Research (CIHR), Children's Hospital Research Institute of Manitoba, Research Manitoba, Women and Children's Health Research Institute, University of Alberta, Alberta Children's Hospital Research Institute, The Hospital for Sick Children, Department of Pediatrics, Western University, St. Justine's Hospital
Bronchiolitis
12/24
06/25
NCT05802992: The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients

Recruiting
3
30
RoW
Colchicine, Lenalidomide, Dexamethasone
Affiliated Hospital of Nantong University
Multiple Myeloma
12/24
12/24
NCT05872893: Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone

Recruiting
3
40
RoW
Ondansetron, Dexamethasone
Immune Oncology Research Institute
Pediatric Cancer
01/25
01/25
NCT04512235 / 2020-000713-32: A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis

Active, not recruiting
3
267
Europe, Canada, Japan, US, RoW
CAEL-101, Anselamimab, Placebo, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
Alexion Pharmaceuticals, Inc.
AL Amyloidosis
03/25
03/27
NCT05347381: Selinexol Combined With Dexamethasone in the Treatment of CAEBV

Not yet recruiting
3
6
RoW
Selinexol and Dexamethasone
Beijing Friendship Hospital
CAEBV
04/25
04/25
GMMG-HD7, NCT03617731 / 2017-004768-37: Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

Calendar Jan 2025 - Dec 2025: From GMMG HD7 trial for newly diagnosed multiple myeloma
Calendar Jan 2024 - Dec 2024: Submission for newly diagnosed multiple myeloma (transplant eligible)
Hourglass Oct 2021 - Dec 2021 : From first part of trial in newly diagnosed multiple myeloma
Active, not recruiting
3
662
Europe
Lenalidomide, Revlimid, Bortezomib, Velcade, Dexamethasone, Isatuximab
University of Heidelberg Medical Center
Multiple Myeloma
05/25
12/25
Perseus, NCT03710603 / 2018-002992-16: Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

Hourglass Jan 2022 - Dec 2022 : From PERSEUS trial in combination with Darzalex for 1L multiple myeloma
Active, not recruiting
3
690
Europe, RoW
Daratumumab, velcade (bortezomib), lenalidomide, dexamethasone, velcade, bortezomib, Lenalidomide
European Myeloma Network, Janssen Research & Development, LLC
Multiple Myeloma
05/25
11/29
RODEX, NCT05325593 / 2021-006970-22: Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia

Recruiting
3
126
Europe
romiplostim plus dexamethasone, ROM + DEX, Dexamethasone, DEX
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla, Ministerio de Sanidad, Consumo y Bienestar Social
Primary Immune Thrombocytopenia
06/26
09/26
NCT03974789: Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms

Recruiting
3
380
Europe
Blood test, 24-hour Urine test, Saliva swab, Dexamethasone test
Centre Hospitalier Universitaire de Nīmes
Cushing Disease
07/25
07/25
NCT05804032 / 2022-000996-38: Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Recruiting
3
514
Europe
Isatuximab, Sarclisa, Lenalidomide, Bortezomib, Velcade, Dexamethasone
University of Heidelberg Medical Center, Deutsche Studiengruppe Multiples Myelom (DSMM), KKS Netzwerk, Sanofi
Multiple Myeloma
07/25
07/26
IsKia, NCT04483739 / 2019-004844-32: Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation ( TRIAL)

Active, not recruiting
3
302
Europe, RoW
Carfilzomib Lenalidomide Dexamethasone, KRd, Isatuximab Carfilzomib Lenalidomide Dexamethasone, Isa-KRD
European Myeloma Network, EMN Research Italy, Sanofi, Amgen
Multiple Myeloma
07/25
12/32
NCT04474223: Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)

Recruiting
3
1300
Canada, US
Dexamethasone, IVIG
NYU Langone Health
AVB - Atrioventricular Block, Fetal AVB
08/26
10/26
MajesTEC-3, NCT05083169 / 2020-004742-11: A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

Active, not recruiting
3
587
Europe, Canada, Japan, US, RoW
Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Teclistamab, JNJ-64007957
Janssen Research & Development, LLC, Janssen Research & Development, LLC
Multiple Myeloma
08/25
12/28
MajesTEC-9, NCT05572515: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
3
590
Europe, Canada, Japan, US, RoW
Teclistamab, JNJ-64007957, Pomalidomide, Bortezomib, Dexamethasone, Carfilzomib
Janssen Research & Development, LLC
Relapsed or Refractory Multiple Myeloma
10/25
08/31
NCT03652064 / 2018-001545-13: A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Hourglass Jan 2023 - Dec 2023 : Data from CEPHEUS trial for transplant ineligible frontline multiple myeloma
Active, not recruiting
3
395
Europe, Canada, Japan, US, RoW
Daratumumab, JNJ-54767414, DARZALEX, Bortezomib, Velcade, Lenalidomide, Revlimid, Dexamethasone
Janssen Research & Development, LLC
Multiple Myeloma
08/25
10/28
DEXAML-03, NCT03765541 / 2018-001467-23: Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia

Recruiting
3
142
Europe
Dexamethasone, Amsacrine, Cytarabine, Azacitidine
University Hospital, Toulouse
Relapsed or Refractory Acute Myeloid Leukemia
12/25
12/25
MonumenTAL-3, NCT05455320 / 2021-000202-22: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

Recruiting
3
810
Europe, Japan, US, RoW
Talquetamab, JNJ-64407564, Daratumumab, Pomalidomide, Dexamethasone
Janssen Research & Development, LLC, Janssen Research & Development, LLC
Relapsed or Refractory Multiple Myeloma
02/26
09/29
CANOVA, NCT03539744 / 2017-003838-88: A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Jan 2023 - Jun 2023: Data from CANOVA trial for r/r multiple myeloma
Active, not recruiting
3
265
Europe, Canada, Japan, US, RoW
Pomalidomide, Pomalyst, Dexamethasone, Venetoclax, ABT-199, GDC-0199
AbbVie, Roche-Genentech
Multiple Myeloma
08/26
08/26
ACCoRd, NCT03562169: The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII

Recruiting
3
406
Europe
Ixazomib, thalidomide, & dexamethasone (ITD) re-induction, Conventional autologous stem cell transplant (ASCT-con), Augmented autologous stem cell transplant (ASCT-aug), ITD consolidation and ixazomib maintenance vs. No further therapy
University of Leeds, Cancer Research UK, Takeda
Multiple Myeloma
03/26
03/27
NCT05028348 / 2021-001691-41: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Calendar Jul 2024 - Dec 2024: Top-line data from XPORT-MM-031 trial in combination with pomalidomide and dexamethasone for multiple myeloma
Jun 2023 - Dec 2023: Completion of enrolment of trial in combination with pomalidomide and dexamethasone for multiple myeloma
Recruiting
3
222
Europe, US
Selinexor, KPT-330, Elotuzumab, Pomalidomide, Dexamethasone Oral
Stichting European Myeloma Network, Karyopharm Therapeutics Inc
Multiple Myeloma
03/26
03/29
EXCALIBER, NCT04975997 / 2020-000431-49: Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Recruiting
3
864
Europe, Canada, Japan, US, RoW
Dexamethasone, Daratumumab, DARZALEX FASPRO, Bortezomib, Iberdomide, CC-220, BMS-986382
Celgene
Multiple Myeloma
03/26
06/32
NCT05776940: Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis

Not yet recruiting
3
116
NA
Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules combined with Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab, Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules + Routine therapy, Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab, Routine therapy
Air Force Military Medical University, China
Immunoglobulin Light-chain Amyloidosis
03/26
03/26
IDRIS, NCT02544308 / 2015-001355-76: Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma

Active, not recruiting
3
36
Europe
Lenalidomide, Revlimid, Dexamethasone, No further treatment
University College, London, Cancer Research UK, Celgene
Plasmacytoma
04/26
12/26
IMROZ, NCT03319667 / 2017-002238-21: Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant

Calendar Jan 2024 - Dec 2024: Submission for newly diagnosed multiple myeloma (based on IMROZ trial)
Hourglass Oct 2023 - Dec 2023 : Pivotal data readout from IMROZ trial for 1L multiple myeloma
Hourglass Oct 2021 - Mar 2022 : Regulatory submissions for NDMM (based on IMROZ trial) in EU
Hourglass Jan 2021 - Dec 2021 : Primary data from IMROZ trial for newly diagnosed multiple myeloma
Active, not recruiting
3
475
Europe, Japan, US, RoW
Isatuximab SAR650984, Sarclisa, Bortezomib, Velcade®, Lenalidomide, Dexamethasone
Sanofi
Plasma Cell Myeloma
04/26
06/27
CARTITUDE-4, NCT04181827 / 2019-001413-16: A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

Hourglass Sep 2023 - Sep 2023 : Safety and efficacy data from CARTITUDE-4 trial in adults with relapsed and lenalidomide-refractory multiple myeloma
Hourglass Jun 2023 - Jun 2023 : Data from CARTITUDE-4 trial for relapsed/refractory multiple myeloma at EHA 2023
Checkmark Data from CARTITUDE-4 trial for relapsed/refractory multiple myeloma
Jan 2023 - Jan 2023: Data from CARTITUDE-4 trial for relapsed/refractory multiple myeloma
Active, not recruiting
3
419
Europe, Japan, US, RoW
JNJ-68284528, Cilta-cel, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab
Janssen Research & Development, LLC
Multiple Myeloma
05/24
06/27
CARTITUDE-5, NCT04923893 / 2021-001242-35: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

Recruiting
3
650
Europe, Canada, Japan, US, RoW
Bortezomib, Dexamethasone, Lenalidomide, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine
Janssen Research & Development, LLC, Janssen Research & Development, LLC, Janssen Cilag SpA
Multiple Myeloma
06/26
12/34
ChiCTR2000035264: Chinese Children's Cancer Group Acute Lymphoblastic Leukemia-2020 Project

Recruiting
3
5700
 
2 courses of high dose methotrexate or 4 courses of high dose methotrexate ;Dexamethasone 8 mg/m2 per day or prednisone 60 mg/m2 per day during remission induction
Shanghai Children's Medical Center; Shanghai Children's Medical Center, VIVA-China Children’s Cancer Foundation
Acute lymphoblastic leukemia
 
 
IFM2017_03, NCT03993912: Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

Active, not recruiting
3
294
Europe
Daratumumab SC in combination with Lenalidomide, Lenalidomide PO (25mg), Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression
University Hospital, Lille
Multiple Myeloma
10/26
10/27
ChiCTR2300074647: Antenatal corticosteroids prior to early term elective caesarean section: a multi-center, randomized controlled trial

Not yet recruiting
3
1500
 
4 doses of 6 mg dexamethasone sodium phosphate by intramuscular injection into the buttock, 12 hours apart given within seven days of elective caesarean section ;None
Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hostipal; Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hostipal, National key research and development program(2022YFC2703503)
early term labor
 
 
MRD-CONFIRM, NCT05203003: Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.

Recruiting
3
260
Europe
Assessment of MRD
Assistance Publique - Hôpitaux de Paris
Multiple Myeloma
04/27
12/28
GEM21menos65, NCT05558319: NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide

Not yet recruiting
3
480
Europe
Bortezomib, Isatuximab, Iberdomide, Lenalidomide, Dexamethasone
PETHEMA Foundation, Bristol-Myers Squibb, Sanofi, Adknoma, Start from scratch
Newly Diagnosed Multiple Myeloma
04/27
04/29
KarMMa-3, NCT03651128 / 2018-001023-38: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Hourglass Jun 2023 - Jun 2023 : Subgroup analysis of outcomes for patients with high-risk r/r multiple myeloma from the KarMMa-3 trial at EHA 2023
Checkmark Data from KarMMa-3 trial for 3L multiple myeloma
Aug 2022 - Aug 2022: Data from KarMMa-3 trial for 3L multiple myeloma
Active, not recruiting
3
381
Europe, Canada, Japan, US
bb2121, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Ixazomib, Lenalidomide, Carfilzomib, Elotuzumab
Celgene
Multiple Myeloma
04/27
04/27
ChiCTR2200064576: Noninferiority of sarperin versus dexamethasone aerosol inhalation in the prevention and treatment of radiation-induced oral mucositis in nasopharyngeal carcinoma: a parallel, randomized controlled study

Recruiting
3
68
 
Concurrent chemoradiotherapy (CCRT) combined with atomized inhalation of salpeilin ;CCRT combined with dexamethasone aerosol inhalation
Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University, In-hospital subsidy
Radiation-induced oral mucositis
 
 
DANOHCA, NCT05895838: The Danish Out-of-Hospital Cardiac Arrest Study

Recruiting
3
1000
Europe
Dexamethasone, Dexavit, Backrest elevation, Early wakeup call, Olanzapine
Christian Hassager
Out-Of-Hospital Cardiac Arrest, Post-Cardiac Arrest Syndrome
09/27
12/27
AALL1631, NCT03007147 / 2017-000705-20: Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Recruiting
3
475
Europe, Canada, US, RoW
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Calaspargase Pegol, Asparaginase (Escherichia coli Isoenzyme II), Conjugate with alpha-(((2,5-Dioxo-1-pyrrolidinyl)oxy)carbonyl)-omega-methoxypoly(oxy-1,2-ethanediyl), Asparlas, Calaspargase Pegol-mknl, EZN-2285, SC-PEG E. Coli L-Asparaginase, Succinimidyl Carbonate Monomethoxypolyethylene Glycol E. coli L-Asparaginase, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin Hydrochloride, Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Dexrazoxane Hydrochloride, Cardioxane, Totect, Zinecard, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Imatinib Mesylate, CGP 57148, CGP57148B, Gleevec, Glivec, STI 571, STI-571, STI571, Laboratory Biomarker Analysis, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, Folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Mercaptopurine, 3H-Purine-6-thiol, 6 MP, 6 Thiohypoxanthine, 6 Thiopurine, 6-Mercaptopurine, 6-Mercaptopurine Monohydrate, 6-MP, 6-Purinethiol, 6-Thiopurine, 6-Thioxopurine, 6H-Purine-6-thione, 1,7-dihydro- (9CI), 7-Mercapto-1,3,4,6-tetrazaindene, Alti-Mercaptopurine, Azathiopurine, Bw 57-323H, Flocofil, Ismipur, Leukerin, Leupurin, Mercaleukim, Mercaleukin, Mercaptina, Mercaptopurinum, Mercapurin, Mern, NCI-C04886, Puri-Nethol, Purimethol, Purine, 6-mercapto-, Purine-6-thiol (8CI), Purine-6-thiol, monohydrate, Purinethiol, Purinethol, U-4748, WR-2785, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Methylprednisolone, Adlone, Caberdelta M, DepMedalone, Depo Moderin, Depo-Nisolone, Duralone, Emmetipi, Esametone, Firmacort, Medlone 21, Medrate, Medrol, Medrol Veriderm, Medrone, Mega-Star, Meprolone, Methylprednisolonum, Metilbetasone Solubile, Metrocort, Metypresol, Metysolon, Predni-M-Tablinen, Prednilen, Radilem, Sieropresol, Solpredone, Summicort, Urbason, Veriderm Medrol, Wyacort, Pegaspargase, L-Asparaginase with Polyethylene Glycol, Oncaspar, Oncaspar-IV, PEG-Asparaginase, PEG-L-Asparaginase, PEG-L-Asparaginase (Enzon - Kyowa Hakko), PEGLA, Polyethylene Glycol L-Asparaginase, Polyethylene Glycol-L-Asparaginase, Prednisolone, (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, .delta.1-Hydrocortisone, Adnisolone, Aprednislon, Capsoid, Cortalone, Cortisolone, Dacortin H, Decaprednil, Decortin H, Delta(1)Hydrocortisone, Delta- Cortef, Delta-Cortef, Delta-Diona, Delta-F, Delta-Phoricol, Delta1-dehydro-hydrocortisone, Deltacortril, Deltahydrocortisone, Deltasolone, Deltidrosol, Dhasolone, Di-Adreson-F, Dontisolon D, Estilsona, Fisopred, Frisolona, Gupisone, Hostacortin H, Hydeltra, Hydeltrasol, Klismacort, Kuhlprednon, Lenisolone, Lepi-Cortinolo, Linola-H N, Linola-H-Fett N, Longiprednil, Metacortandralone, Meti Derm, Meticortelone, Opredsone, Panafcortelone, Precortisyl, Pred-Clysma, Predeltilone, Predni-Coelin, Predni-Helvacort, Prednicortelone, Prednisolonum, Prelone, Prenilone, Sterane, Questionnaire Administration, Therapeutic Hydrocortisone, Aeroseb-HC, Barseb HC, Barseb-HC, Cetacort, Cort-Dome, Cortef, Cortenema, Cortifan, Cortisol, Cortispray, Cortril, Dermacort, Domolene, Eldecort, Hautosone, Heb-Cort, Hydrocortisone, Hydrocortone, Hytone, Komed-HC, Nutracort, Proctocort, Rectoid, Thioguanine, 2-Amino 6MP, 2-Amino-1,7-dihydro-6H-purine-6-thione, 2-Amino-6-mercaptopurine, 2-Amino-6-purinethiol, 2-Aminopurin-6-thiol, 2-Aminopurine-6(1H)-thione, 2-Aminopurine-6-thiol, 2-Aminopurine-6-thiol Hemihydrate, 2-Mercapto-6-aminopurine, 6-Amino-2-mercaptopurine, 6-Mercapto-2-aminopurine, 6-Mercaptoguanine, 6-TG, 6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI), BW 5071, Lanvis, Tabloid, Thioguanine Hemihydrate, Thioguanine Hydrate, Tioguanin, Tioguanine, Wellcome U3B, WR-1141, X 27, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Children's Oncology Group, EsPhALL Network/ BFM Study Group, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
09/27
09/27
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting
3
482
Europe
Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)
Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH
Multiple Myeloma
03/28
03/33
MagnetisMM-6, NCT05623020 / 2021-000803-20: A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

Recruiting
3
966
Europe, Canada, Japan, RoW
Elranatamab, Daratumumab, Lenalidomide, Dexamethasone
Pfizer, Pfizer, Inc.
Multiple Myeloma
03/28
11/31
ITHACA, NCT04270409 / 2019-003139-47: A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma

Active, not recruiting
3
337
Europe, Canada, Japan, US, RoW
Isatuximab SAR650984, Sarclisa, Lenalidomide, Dexamethasone, Montelukast or equivalent, Acetaminophen, Diphenhydramine or equivalent, Methylprednisolone or equivalent
Sanofi
Plasma Cell Myeloma
11/30
10/33
MajesTEC-7, NCT05552222 / 2022-000909-28: A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Recruiting
3
1590
Europe, Canada, Japan, RoW
Teclistamab, JNJ-64007957, Daratumumab, Lenalidomide, Dexamethasone, Talquetamab, JNJ-64407564
Janssen Research & Development, LLC, Janssen Research & Development, LLC
Multiple Myeloma
04/31
10/33
DSMM XVII, NCT03948035 / 2017-001616-11: Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

Active, not recruiting
3
576
Europe
Elotuzumab, Empliciti®, Carfilzomib, Kyprolis®, Lenalidomide, Revlimid®, Dexamethasone, Fortecortin®, autologous stem cell transplant
Wuerzburg University Hospital, ClinAssess GmbH, Arbeitsgemeinschaft medikamentoese Tumortherapie
Newly Diagnosed Multiple Myeloma
08/29
08/29
CARTITUDE-6, NCT05257083: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Recruiting
3
750
Europe, Canada, Japan, US, RoW
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine
Stichting European Myeloma Network, Janssen Research & Development, LLC
Multiple Myeloma
06/33
08/40
ACTRN12619001349134: The effects of submucosal administration of methylprednisolone and dexamethasone in comparison to control group on pain, swelling, and trismus after third molar surgery

Not yet recruiting
2/3
90
 
Dr Kinza Ayub, Dr Kinza Ayub
Third molar surgery, Pericoronitis
 
 
2010-021445-42: A study in which is investigated if the medicine bortezomib is effective in patients with AL amyloidosis

Ongoing
2/3
50
Europe
Fortecortin, Powder for solution for injection, Velcade
HOVON Foundation, Dutch Cancer Society, Janssens Pharma NV
AL Amyloidosis, AL amyloidosis, Diseases [C] - Cancer [C04]
 
 
2010-021091-28: A clinical study to determine whether a new drug masitinib is safe and effective in cancer of the white blood cells.

Ongoing
2/3
267
Europe, RoW
Masitinib mesylate, Gemcitabine, Dexamethasone, AB1010, Film-coated tablet, Powder for infusion, Tablet, Gemcitabine, Dexamethasone
AB Science, AB Science
Relapsed or refractory peripheral T-cell lymphoma, Cancer of the white blood cells (T-lymphocytes), Diseases [C] - Cancer [C04]
 
 
2014-002146-44: Blood cancer in younger adults (18-59 years) Cancer du sang de l'adulte jeune (18-59 ans)

Ongoing
2/3
1040
Europe
Atriance, Tasigna, cyclophosphamide, méthotrexate, vincristine, cytarabine, Etoposide, dexamethasone, prednisone, 6-mercaptopurine, daunorubicine, idarubicine, L-Asparaginase, G-CSF, imatinib, BLINATUMOMAB, Nélarabine, Nilotinib, Solution for infusion, Capsule, Powder for injection, Solution for injection, Tablet, Powder for infusion, Powder and solvent for solution for injection, Powder for concentrate and solution for solution for infusion, Atriance, Tasigna, cyclophosphamide, méthotrexate, vincristine, cytarabine, Etoposide, dexamethasone, prednisone, 6-mercaptopurine, daunorubicine, idarubicine, L-Asparaginase, G-CSF, imatinib, Blincyto
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), DGOS
Patients with de novo acute lymphoblastic leukemia of young adults. -GRAALL-2014/B: Ph- B lineage ALL -GRAALL-2014/T et ATRIALL: T-ALL -GRAAPH-2014: ALL Ph+ Patients présentant une Leucémie Aigue Lymphoblastique de l'adulte jeune de novo. -GRAALL-2014/B : LAL de la lignée B Ph- -GRAALL-2014/T et ATRIALL : LAL T -GRAAPH-2014 : LAL Ph+, Acute Lymphoblastic Leukemia Leucémie Lymphoblastique Aigüe, Diseases [C] - Cancer [C04]
 
 
2017-003189-29: multicentric randomized trial, compared abiraterone + dexamethasone versus standard abiraterone + prednisone in patients resistant-castration in metastatic prostate cancer Essai multicentrique randomisé, comparant un traitement par abiraterone + dexamethasone versus abiraterone + prednisone, au moment de la progression biologique sous abiraterone + prednisone, chez des patients ayant un cancer de prostate métastatique en première ligne de résistance à la castration.

Ongoing
2/3
281
Europe
DEXAMETHASONE, Prednisone, Abiraterone, Buccal tablet, Tablet, DECTANCYL 0.5 mg, CORTANCYL 5mg, Zytiga 250 mg
L'Institut Mutualiste Montsouris, Unité de Méthodologie et de Qualité de vie en Cancérologie
Metastatic castration resistant prostate cancer patients under abiraterone + prednisone with exclusive biological progression (PSA progression on the PSAWG3 criteria) Patients atteints d’adénocarcinomes de prostate métastatiques en phase de résistance à la castration, sous Abiratérone + Prednisone, avec progression biologique exclusive (progression PSA sur les critères PSAWG3), Metastatic castration resistant prostate cancer patients under abiraterone + prednisone with exclusive biological progression (PSA progression) Patients atteints d’adénocarcinomes de prostate métastatiques en phase de résistance à la castration, sous Abiratérone + Prednisone, avec progression biologique exclusive (progression PSA), Diseases [C] - Cancer [C04]
 
 
ChiCTR1900025227: A randomized, open, parallel controlled phase II clinical study comparing the efficacy and safety of dexamethasone, palonosetron or aprepitant in the control of acute and delayed vomiting in non-small cell lung cancer patients receiving multiple moderately emetogenic chemotherapy regimens

Not yet recruiting
2/3
200
 
palonosetron, and dexamethasone ;dexamethasone,aprepitant and palonosetron
Hunan Cancer Hospital; Hunan Cancer Hospital, National Cancer Center
non-small cell lung cancer
 
 
2019-004401-27: The REMNANT (RElapse from Mrd Negativity As iNdication for Treatment) study

Not yet recruiting
2/3
391
Europe
Velcade, Revlimid, Dexamethasone, Darzalex, Kyprolis, Powder for injection, Tablet, Concentrate for solution for infusion, Powder for solution for infusion, Velcade, Revlimid, Darzalex, Kyprolis
Oslo University Hospital, Department of Hematology, Oslo University Hospital
Multiple myeloma, Multiple myeloma, Diseases [C] - Cancer [C04]
 
 
ChiCTR1900025211: A randomized, open label, controlled phase II/III study of comparing efficacy and safety of dexamethasone, aprepitant, palonosetron with/without mirtazapine in delayed vomiting in patients with non-small cell lung cancer

Recruiting
2/3
300
 
dexamethasone, aprepitant, palonosetron ;dexamethasone, aprepitant, palonosetron and mirtazapine
Hu'nan Cancer Hospital; Hunan Cancer Hospital, National Cancer Center
non-small cell lung cancer
 
 
NCT03692754: Atorvastatin in Management of Newly Diagnosed ITP

Not yet recruiting
2/3
30
RoW
Atorvastatin 20mg, atorvastatin calcium, Atorvastatin 10mg, Dexamethasone
Shandong University
Immune Thrombocytopenia, Purpura, Thrombocytopenic
12/21
12/23
NCT05145543: Effect of Topically Administered Levobupivacaine- Fentanyl Versus Levobupivacaine- Dexamethasone Combination in the Control of Pain After Endoscopic Sinus Surgery

Recruiting
2/3
80
RoW
Saline 0.9%, Levobupivacaine Hydrochloride, Fentanyl, Dexamethasone
Assiut University
Endoscopic Sinus Surgery, Fentanyl
03/22
03/22
NCT03668639: Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin

Recruiting
2/3
80
Europe
Akynzeo, Dexamethasone
Christina Ruhlmann, Helsinn Healthcare SA
Chemotherapy-induced Nausea and Vomiting, Adverse Event, Cervical Cancer
03/23
04/23
NCT05553496: Assessment of Rituximab Therapeutic Response Versus Conventional Treatment

Not yet recruiting
2/3
40
NA
Rituximab, Dexamethasone, Tacrolimus, Mycophenloatemofetil, Cyclophosphamide, Cyclosporine
Ain Shams University
Pharmacological Action
04/23
10/23
NCT06166108: Magnesium Sulphate Versus Dexamethasone as an Adjuvant to Bupivacaine in TAP Block for Abdominal Hysterectomy

Not yet recruiting
2/3
56
NA
transversus abdominis plane (TAP) block in Abdominal hysterectomy
Assiut University
TAP Block
11/24
11/25
NATADEX, NCT04452565: NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection

Recruiting
2/3
525
US
Drug: NA-831, NA-831 and Atazanavir, and Atazanavir, NA-831and Dexamethasone, Dexamethasone, Atazanavir and Dexamethasone
NeuroActiva, Inc., Biomed Industries, Inc.
Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2
12/23
12/23
Any, NCT05705128: Dexmedetomidine in Postoperative Analgesia

Recruiting
2/3
100
RoW
Dexmedetomidine
New Valley University
Pain Management
06/24
08/24
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Recruiting
2/3
3100
Europe
Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax
University Hospital, Angers
Acute Myeloid Leukemia (AML)
06/24
 
NCT05546359: Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients

Recruiting
2/3
410
Europe, Canada, US
Amisulpride Injection, Barhemsys, Dexamethasone, Decadron
Acacia Pharma Ltd, Amicus CD LLC, Premier Research Group plc
Nausea and Vomiting, Postoperative
06/25
12/25
NCT06212336: ISTH/ANRS 0409s INTEGRATE Lassa Fever Study

Not yet recruiting
2/3
1755
NA
Favipiravir, Ribavirin, Standard of care, Dexamethasone
Irrua Specialist Teaching Hospital, Alliance for International Medical Action, University of Bordeaux, Bernhard Nocht Institute for Tropical Medicine, Federal Medical Centre, Owo, Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire, Fondation pour la Recherche Scientifique, Benin, Médecins Sans Frontières, Belgium, Alex Ekwueme Federal University Teaching Hospital, Donka Hospital, Conakry, Centre de Recherche Médicale de Lambaréné, University of Hamburg-Eppendorf, Phebe Hospital, Liberia, University of North Carolina, ANRS, Emerging Infectious Diseases
Lassa Fever
06/27
06/27
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/Refractory Diffuse Large B-cell Lymphoma
12/24
12/25
NCT05367271: The Efficacy of Botulinum Toxin vs. Corticosteroid for the Treatment of Refractory Plantar Fasciitis

Active, not recruiting
2/3
62
US
Botulinum Toxin A, OnabotulinumtoxinA, BTX-A, Dexamethasone, Cortisone
Western Institute for Veterans Research
Plantar Fasciitis
04/24
10/24
ELIAS, NCT05665140: Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients

Recruiting
2/3
100
Europe
Isatuximab, Sarclisa®, Lenalidomide, Lenalidomid®, Bortezomib, Velcade®, Dexamethasone, autologous stem cell transplant
University Hopsital Schleswig Holstein Campus Lübeck
Newly Diagnosed Multiple Myeloma
08/27
10/28
Glo-BNHL, NCT05991388: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

Not yet recruiting
2/3
210
NA
Odronextamab, REGN-1979, Loncastuximab tesirine, ADCT-402, Rituximab, Ifosfamide, Carboplatin, Etoposide, Etoposide Phosphate, Dexamethasone, CAR T-cells (TBC)
University of Birmingham, Cancer Research UK, Fight Kids Cancer, Regeneron Pharmaceuticals, ADC Therapeutics SA
B-cell Non Hodgkin Lymphoma
05/31
05/33
REMNANT, NCT04513639: The Relapse From MRD Negativity as Indication for Treatment () Study

Recruiting
2/3
176
Europe
Early treatment of relapse with carfilzomib, dexamethasone, daratumumab, DKd, Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab
Oslo University Hospital, St. Olavs Hospital, Haukeland University Hospital, University Hospital of North Norway, University Hospital, Akershus, Helse Stavanger HF, Førde Central Hospital, Sorlandet Hospital HF, Nordlandssykehuset HF, The Hospital of Vestfold, Helse Nord-Trøndelag HF, Alesund Hospital, Sykehuset Ostfold
Multiple Myeloma
06/31
06/32
 

Download Options